Clinical significance of chromodomain helicase/ATPase DNA binding protein 1‑like and human mutL homolog 1 gene expression in cholangiocarcinoma

Hua,Jingwen; Li,Shiniao; Huang,Changwen

doi:10.3892/ol.2018.9043

Clinical significance of chromodomain helicase/ATPase DNA binding protein 1‑like and human mutL homolog 1 gene expression in cholangiocarcinoma

Authors:
- Jingwen Hua
- Shiniao Li
- Changwen Huang
View Affiliations

Affiliations: Department of Oncological Surgery, Xinyi People's Hospital, Xuzhou, Jiangsu 221400, P.R. China, Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, P.R. China
Published online on: June 28, 2018 https://doi.org/10.3892/ol.2018.9043
Pages: 2989-2994
Copyright: © Hua et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma is a highly malignant form of gastrointestinal cancer with an unfavorable prognosis. The novel oncogene chromodomain helicase/ATPase DNA binding protein 1‑like (CHD1L) has been confirmed to serve a vital role in numerous types of cancer, including liver cancer. Mismatch repair (MMR) is a common DNA repair process that contributes to the preservation of the integrity and stability of genetic substances. Human mutL homolog 1 gene (hMLH1) is an important MMR protein family member. The present study aimed to evaluate the pathological and clinical features of cholangiocarcinoma, and to investigate the clinical significance of CHD1L and hMLH1 expression in cholangiocarcinoma. A total of 108 samples from cholangiocarcinoma tumor tissues and 60 samples from normal bile duct tissue were obtained from patients admitted to The Second Affiliated Hospital of Nanchang University between May 2005 and May 2014. All cholangiocarcinoma cases were pathologically confirmed. The expression of CHD1L and hMLH1 was examined by immunohistochemistry analysis. The expression of CHD1L in cholangiocarcinoma (94.44%) was significantly higher than in normal bile duct tissues (40.00%). CHD1L expression was associated with gallstone history, serum carbohydrate antigen 19‑9 (CA19‑9) level and Tumor‑Node‑Metastasis (TNM) stage (P<0.05). hMLH1 expression in cholangiocarcinoma (77.78%) was significantly lower than in normal bile duct tissues (96.67%), and was associated with gender, age, serum CA19‑9 level, the presence of hepatitis B virus surface antigen, TNM stage and tumor diameter (P<0.05). Kaplan‑Meier survival curve analysis indicated that the 3‑year accumulative survival rates for CHD1L‑positive and ‑negative patients differed significantly (P<0.05; 17.90 and 83.33%, respectively). There was no statistically significant difference (P>0.05) between the 3‑year accumulate survival rates for hMLH1‑positive and ‑negative patients (38.90 and 33.30%, respectively). High CHD1L expression and low hMLH1 expression levels were observed in patients with cholangiocarcinoma, and their abnormal expression patterns were associated with the progression of malignancy and an unfavorable disease prognosis. Therefore, CHD1L and hMLH1 may be potential prognostic biomarkers for cholangiocarcinoma.

View Figures

View References

1	Ghouri YA, Mian I and Blechacz B: Cancer review: Cholangiocarcinoma. J Carcinog. 14:12015. View Article : Google Scholar : PubMed/NCBI
2	Wadsworth CA, Lim A, Taylor-Robinson SD and Khan SA: The risk factors and diagnosis of cholangiocarcinoma. Hepatol Int. 7:377–393. 2013. View Article : Google Scholar : PubMed/NCBI
3	Eckel F, Brunner T and Jelic S: ESMO Guidelines Working Group: Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22 Suppl 6:vi40–vi44. 2011. View Article : Google Scholar : PubMed/NCBI
4	Tyson GL and El-Serag HB: Risk factors for cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
5	Schweitzer N and Vogel A: Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 29:345–353. 2015. View Article : Google Scholar : PubMed/NCBI
6	Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, Wang J, Dong SS, Tang KH, Xie D, et al: CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 120:1178–1191. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ahel D, Horejsí Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, Flynn H, Skehel M, West SC, Jackson SP, et al: Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 325:1240–1243. 2009. View Article : Google Scholar : PubMed/NCBI
8	He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D and Yang GF: CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 12:4372012. View Article : Google Scholar : PubMed/NCBI
9	Tian F, Xu F, Zhang ZY, Ge JP, Wei ZF, Xu XF and Cheng W: Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 34:3687–3690. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ji X, Li J, Zhu L, Cai J, Zhang J, Qu Y, Zhang H, Liu B, Zhao R and Zhu Z: CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. J Surg Res. 185:84–91. 2013. View Article : Google Scholar : PubMed/NCBI
11	Su Z, Zhao J, Xian G, Geng W, Rong Z, Wu Y and Qin C: CHD1L is a novel independent prognostic factor for gastric cancer. Clin Transl Oncol. 16:702–707. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yan S, Sorrell M and Berman Z: Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress. Cell Mol Life Sci. 71:3951–3967. 2014. View Article : Google Scholar : PubMed/NCBI
13	Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368:258–261. 1994. View Article : Google Scholar : PubMed/NCBI
14	Zhang R, Qin W, Xu GL, Zeng FF and Li CX: A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis. 14:e80–e89. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gu MJ, Bae YK, Kim A, Hong SM, Yu E, Kim J, Jang KT, Chang HK, Jung ES, Bae HI, et al: Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas. Hepatogastroenterology. 59:2228–2232. 2012.PubMed/NCBI
16	Kuan JC, Wu CC, Sun CA, Chu CM, Lin FG, Hsu CH, Kan PC, Lin SC, Yang T and Chou YC: DNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: Evidence from a clinical cohort study. PLoS One. 10:e01233962015. View Article : Google Scholar : PubMed/NCBI
17	Kamarajah SK, Burns WR, Frankel TL, Cho CS and Nathan H: Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
18	Plevová P, Krepelová A, Papezová M, Sedláková E, Curík R, Foretová L, Navrátilová M, Novotný J, Zapletalová J, Palas J, et al: Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer. Neoplasma. 51:275–284. 2004.PubMed/NCBI
19	Gil-García B and Baladrón V: The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma. Biol Cell. 108:29–40. 2016. View Article : Google Scholar : PubMed/NCBI
20	Sun J, Zhang L, Zhao H, Qiu X, Chen W, Wang D, Ban N, Fan S, Shen C, Xia X, et al: CHD1L regulates cell cycle, apoptosis, and migration in glioma. Cell Mol Neurobiol. 36:565–576. 2016. View Article : Google Scholar : PubMed/NCBI
21	He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ and Xie D: Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 6:31181–31190. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wu J, Zong Y, Fei X, Chen X, Huang O, He J, Chen W, Li Y, Shen K and Zhu L: Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer. PLoS One. 9:e986732014. View Article : Google Scholar : PubMed/NCBI
23	Giedl J, Schneckenpointner R, Filbeck T, Ruemmele P, Hofstaedter F, Burger M, Hartmann A and Stoehr R: Low frequency of HNPCC-associated microsatellite instability and aberrant MMR protein expression in early-onset bladder cancer. Am J Clin Pathol. 142:634–639. 2014. View Article : Google Scholar : PubMed/NCBI
24	Park JW, Chang HJ, Park S, Kim BC, Kim DY, Baek JY, Kim SY, Oh JH, Choi HS, Park SC and Jeong SY: Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers. Ann Surg Oncol. 17:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
25	Vageli D, Daniil Z, Dahabreh J, Karagianni E, Vamvakopoulou DN, Ioannou MG, Scarpinato K, Vamvakopoulos NC, Gourgoulianis KI and Koukoulis GK: Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer. 64:282–288. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nam TK, Lee JH, Cho SH, Chung IJ, Ahn SJ, Song JY, Yoon MS, Chung WK and Nah BS: Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett. 260:109–117. 2008. View Article : Google Scholar : PubMed/NCBI